CVRx, Inc. (CVRX)
NASDAQ: CVRX · Real-Time Price · USD
13.52
+0.10 (0.75%)
Nov 20, 2024, 4:00 PM EST - Market closed
Company Description
CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases.
The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure.
It sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, and internationally.
The company was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
CVRx, Inc.
Country | United States |
Founded | 2000 |
IPO Date | Jun 30, 2021 |
Industry | Medical Devices |
Sector | Healthcare |
Employees | 200 |
CEO | Kevin Hykes |
Contact Details
Address: 9201 West Broadway Avenue, Suite 650 Minneapolis, Minnesota 55445 United States | |
Phone | 763 416 2840 |
Website | cvrx.com |
Stock Details
Ticker Symbol | CVRX |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
IPO Price | $18.00 |
CIK Code | 0001235912 |
CUSIP Number | 126638105 |
ISIN Number | US1266381052 |
SIC Code | 3841 |
Key Executives
Name | Position |
---|---|
Kevin Hykes | President, Chief Executive Officer and Director |
Jared Oasheim | Chief Financial Officer |
Paul Verrastro | Chief Marketing and Strategy Officer |
Paul Pignato | Vice President of Operations |
Jonelle R. Burnham | Vice President and General Counsel |
Tonya A. Austin SPHR | Chief Human Resources Officer |
Jennifer E. Englund | Senior Vice President of Global Clinical Affairs |
Dr. Philip B. Adamson M.D., M.Sc. | Chief Medical Officer |
Bonnie Handke M.B.A., R.N. | Senior Vice President of Patient Access, Reimbursement, and Healthcare Economics |
Robert Allen John | Chief Revenue Officer |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Nov 19, 2024 | 144 | Filing |
Nov 18, 2024 | 144 | Filing |
Nov 7, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
Nov 5, 2024 | 144 | Filing |
Nov 5, 2024 | 144 | Filing |
Nov 4, 2024 | 8-K | Current Report |
Nov 1, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Nov 1, 2024 | 10-Q | Quarterly Report |
Oct 29, 2024 | 8-K | Current Report |
Oct 1, 2024 | 8-K | Current Report |